3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Status
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Lymphoid
3
Other hematologic neoplasm
1
Conditions
Lymphoma, Mantle-Cell
6
Recurrence
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, B-Cell
2
Burkitt Lymphoma
2
Waldenstrom Macroglobulinemia
1
Lymphoma
1
Leukemia, Hairy Cell
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
51
fludarabine
37
Dexamethasone
35
venetoclax
30
pembrolizumab
25
Rituximab
21
pomalidomide
18
Lenalidomide
18
Gemcitabine
17
fludarabine phosphate
15
Etoposide
14
Cytarabine
13
daratumumab
12
carfilzomib
11
Temozolomide
11
Injections
10
Cisplatin
10
Calcium Dobesilate
10
glofitamab
9
Nivolumab
9
Bortezomib
9
Azacitidine
9
selinexor
8
Vincristine
8
Immunotherapy, Adoptive
8
Carboplatin
8
obinutuzumab
7
cemiplimab
7
Drug Therapy
7
Bevacizumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recurrence
×
brexucabtagene autoleucel
×
1 year
×
Clear all
NCT02625480
2026-04-09
ZUMA-4
Gilead Sciences
Phase 1/2
Completed
95 enrolled
NCT05537766
2026-03-10
ZUMA-25
Gilead Sciences
Phase 2
Terminated
19 enrolled
28 charts
NCT06253663
2025-12-16
JKART-1
Gilead Sciences
Phase 2
Active not recruiting
25 enrolled